AIRSUPRA is a pressurized inhalation suspension combining 90 mcg of salbutamol (a short-acting beta2-agonist) and 80 mcg of budesonide (an inhaled corticosteroid) per actuation.
It is indicated for the as-needed treatment or prevention of bronchoconstriction and the reduction of exacerbation risk in asthma patients aged 18 and older.
Clinical studies, such as MANDALA and DENALI, demonstrate that the combination significantly reduces severe asthma exacerbations and improves lung function compared to monotherapies.
How To Use
For relief of bronchoconstriction, administer 2 actuations (delivering a total of 180 mcg salbutamol and 160 mcg budesonide) as needed.
For prevention of exercise-induced bronchoconstriction, administer 2 actuations 15 to 30 minutes prior to physical activity.
Do not exceed a maximum of 6 doses (12 inhalations) within a 24-hour period.
No dosage adjustment is required for elderly patients; however, safety and effectiveness have not been established for adolescents aged 12 to 17.
Warnings And Precautions
Contraindicated in patients with known hypersensitivity to salbutamol, budesonide, or any of the formulation excipients.
Patients should seek immediate medical advice if they experience a paradoxical bronchospasm or if increased bronchodilator use is required, as this indicates worsening asthma control.
Use with caution in patients with cardiovascular disorders (e.g., severe heart disease, hypertension), thyrotoxicosis, or hypokalaemia.
Usage during pregnancy or breastfeeding should only be considered if the expected benefit to the mother outweighs the potential risks to the fetus or infant.
Avoid concomitant use with non-selective beta-blockers and exercise caution with strong CYP3A4 inhibitors (e.g., ketoconazole).
Ingredients
Active Ingredients: Salbutamol (90 mcg per actuation) and Budesonide (80 mcg per actuation).
Propellant: Norflurane (HFA-134a).
Excipients: 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC) and Calcium Chloride.
AIRSUPRA is a pressurized inhalation suspension combining 90 mcg of salbutamol (a short-acting beta2-agonist) and 80 mcg of budesonide (an inhaled corticosteroid) per actuation.
It is indicated for the as-needed treatment or prevention of bronchoconstriction and the reduction of exacerbation risk in asthma patients aged 18 and older.
Clinical studies, such as MANDALA and DENALI, demonstrate that the combination significantly reduces severe asthma exacerbations and improves lung function compared to monotherapies.
How To Use
For relief of bronchoconstriction, administer 2 actuations (delivering a total of 180 mcg salbutamol and 160 mcg budesonide) as needed.
For prevention of exercise-induced bronchoconstriction, administer 2 actuations 15 to 30 minutes prior to physical activity.
Do not exceed a maximum of 6 doses (12 inhalations) within a 24-hour period.
No dosage adjustment is required for elderly patients; however, safety and effectiveness have not been established for adolescents aged 12 to 17.
Warnings And Precautions
Contraindicated in patients with known hypersensitivity to salbutamol, budesonide, or any of the formulation excipients.
Patients should seek immediate medical advice if they experience a paradoxical bronchospasm or if increased bronchodilator use is required, as this indicates worsening asthma control.
Use with caution in patients with cardiovascular disorders (e.g., severe heart disease, hypertension), thyrotoxicosis, or hypokalaemia.
Usage during pregnancy or breastfeeding should only be considered if the expected benefit to the mother outweighs the potential risks to the fetus or infant.
Avoid concomitant use with non-selective beta-blockers and exercise caution with strong CYP3A4 inhibitors (e.g., ketoconazole).
Ingredients
Active Ingredients: Salbutamol (90 mcg per actuation) and Budesonide (80 mcg per actuation).
Propellant: Norflurane (HFA-134a).
Excipients: 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC) and Calcium Chloride.